thiogenesis therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
32 Royal Rd, Belmont, Massachusetts, 024...Phone Number
(647) 846-7766Website
www.thiogenesis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About thiogenesis therapeutics
Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing next-generation sulfur-based therapeutics aimed at treating mitochondrial diseases. Their lead product, TTI-0102, is a novel cysteamine prodrug designed to improve tolerability and bioavailability compared to existing thiol therapies. The company targets pediatric diseases with unmet medical needs, including cystinosis, MELAS, and Leigh syndrome, and plans to initiate pivotal clinical trials in the coming years. With proprietary compounds engineered to overcome previous limitations of thiol-based drugs, Thiogenesis aims to address oxidative stress and inflammation in various inherited and acquired mitochondrial conditions.Explore more
thiogenesis therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is thiogenesis therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if thiogenesis therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on thiogenesis therapeutics recently announced quarterly report
Check out if thiogenesis therapeutics is spiking on competitors!
thiogenesis therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when thiogenesis therapeutics launches new products
Funding: Get notified immidiatlly once thiogenesis therapeutics has new funding data
Check if thiogenesis therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at thiogenesis therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at thiogenesis therapeutics
Find more new buyers
Compare Similar Companies to thiogenesis therapeutics
Compare insights from companies similar to thiogenesis therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
thiogenesis therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
thiogenesis therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about thiogenesis therapeutics.
thiogenesis therapeutics financials insights
Gather financial insights about thiogenesis therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$126K
2026
Stock/Share Issuance
$29K
thiogenesis therapeutics Tech Stack
A closer look at the technologies used by thiogenesis therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Funding
Funding
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding thiogenesis therapeutics
Sign Up For FreeTo access detailed company insights
Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing next-generation sulfur-based therapeutics aimed at treating mitochondrial diseases. Their lead product, TTI-0102, is a novel cysteamine prodrug designed to improve tolerability and bioavailability compared to existing thiol therapies. The company targets pediat... Read More
